Advancing Treatment for RDH12-Associated Inherited Retinal Diseases
For families and individuals affected by inherited retinal diseases (IRDs), collaborative developments in research bring vital momentum to the community. According to reports from Ophthalmology Times Europe, Opus Genetics and the Global RDH12 Alliance have announced a strategic partnership to propel gene therapy efforts for retinol dehydrogenase 12 (RDH12) gene mutations.
Key Details of the Partnership
The collaboration centers on OPGx-RDH12, an investigational gene therapy program managed by Opus Genetics targeting Leber congenital amaurosis associated with RDH12 mutations (RDH12-LCA). According to the source material, the Global RDH12 Alliance—a platform uniting IRD advocacy groups such as the U.S.-based “RDH12 Fund for Sight” and the U.K.-based “Eyes on the Future”—will provide up to $1.6 million in funding. The agreement incorporates a risk-sharing structure with performance-based milestones, involving joint efforts on clinical and regulatory strategy.
What This Means for Patients and Families
RDH12-LCA is a rare condition affecting several thousand people globally. Mutations in the RDH12 gene impair protein function in the retina, which can lead to early visual decline by age two and rapid progression during the second decade of life. By uniting patient community perspectives and resources directly with industry expertise, the partnership aims to accelerate the transition of therapies out of the laboratory and into clinical settings.
Looking Ahead
According to the announcement, the shared goal of Opus Genetics and the Global RDH12 Alliance is to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) by late 2025.